2007
DOI: 10.1016/j.drudis.2006.11.009
|View full text |Cite
|
Sign up to set email alerts
|

China's unique position in discovery and preclinical research

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2008
2008
2017
2017

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 16 publications
(10 citation statements)
references
References 3 publications
0
10
0
Order By: Relevance
“…Pharmaceutical companies want to increase their productivity in research, the adaptation during the last decade to do so have been a shift in scientific and technological paradigms emerging in small steps, business model innovation in R&D, increased M&A activities as well as increased early in‐licensing deals and last but not least an increased outsourcing activity to low cost countries such as China or India (Boutellier and Ullman, 2007). Our results show that the communication landscape changes dramatically moving from cell space to multi‐space.…”
Section: Discussion Of Resultsmentioning
confidence: 99%
“…Pharmaceutical companies want to increase their productivity in research, the adaptation during the last decade to do so have been a shift in scientific and technological paradigms emerging in small steps, business model innovation in R&D, increased M&A activities as well as increased early in‐licensing deals and last but not least an increased outsourcing activity to low cost countries such as China or India (Boutellier and Ullman, 2007). Our results show that the communication landscape changes dramatically moving from cell space to multi‐space.…”
Section: Discussion Of Resultsmentioning
confidence: 99%
“…The empirical data from Med Tech concerning this issue is of a diverging kind and it remains somewhat unclear to which extent this might be the case for the company (cf. Boutellier and Ullman, 2007). To prepare for more direct university collaboration in the future, internships are offered to selected university students.…”
Section: Industry-university (I-u) Collaborationsmentioning
confidence: 99%
“…Subsidies and favorable policy measures should be designed and prioritized to strengthen the performance of effective innovators (Nemet, ). The following innovation resources have been identified (Chan et al, ): (1)State‐Owned Enterprises (SOEs) (White, ; Jiang et al, ; Nolan and Yeung, ; Wang et al, ). (2)High‐tech Small‐to‐Medium Enterprises (SMEs) (Jiang et al, ; Boutellier and Ullman, ; Wang et al, ). (3)Multinational Company and subsidiaries (MNCs) (Boutellier and Ullman, ; Ghauri and Rao, ; Han, ). (4)Contract Research/Manufacture Organizations (CRO/CMOs) (Lawrence, ; Singh, ; Boutellier and Ullman, ). (5)University Research Programs (URPs) (Boutellier and Ullman, ; Hong, ; Wang et al, ). (6)Equity Joint Ventures (EJVs) (Nolan and Yeung, ; Boutellier and Ullman, ; Lee, ). (7)Public Research Institutes (Boutellier and Ullman, ; Wang et al, ). (8)Foreign R&D Centers (FR&D) (Lawrence, ; Gassmann et al, ; Un and Cuervo‐Cazurra, ). …”
Section: Case Applicationmentioning
confidence: 99%
“…(1) State-Owned Enterprises (SOEs) (White, 2000;Jiang et al, 2001;Nolan and Yeung, 2001;Wang et al, 2009). (2) High-tech Small-to-Medium Enterprises (SMEs) (Jiang et al, 2001;Boutellier and Ullman, 2007;Wang et al, 2009).…”
Section: Resource Alternativesmentioning
confidence: 99%
See 1 more Smart Citation